IL151530D0 - Compositions containing alpha-2-adrenergic agonist components - Google Patents

Compositions containing alpha-2-adrenergic agonist components

Info

Publication number
IL151530D0
IL151530D0 IL15153001A IL15153001A IL151530D0 IL 151530 D0 IL151530 D0 IL 151530D0 IL 15153001 A IL15153001 A IL 15153001A IL 15153001 A IL15153001 A IL 15153001A IL 151530 D0 IL151530 D0 IL 151530D0
Authority
IL
Israel
Prior art keywords
adrenergic agonist
alpha
components
agonist components
compositions containing
Prior art date
Application number
IL15153001A
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US21820000P priority Critical
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Priority to PCT/US2001/021552 priority patent/WO2002005853A2/en
Publication of IL151530D0 publication Critical patent/IL151530D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL151530(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Abstract

Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
IL15153001A 2000-07-14 2001-07-09 Compositions containing alpha-2-adrenergic agonist components IL151530D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US21820000P true 2000-07-14 2000-07-14
PCT/US2001/021552 WO2002005853A2 (en) 2000-07-14 2001-07-09 Compositions containing alpha-2-adrenergic agonist components

Publications (1)

Publication Number Publication Date
IL151530D0 true IL151530D0 (en) 2003-04-10

Family

ID=22814143

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15153001A IL151530D0 (en) 2000-07-14 2001-07-09 Compositions containing alpha-2-adrenergic agonist components
IL15153002A IL151530A (en) 2000-07-14 2002-08-28 Compositions containing alpha-2-adrenergic agonist components having enhanced solubility

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15153002A IL151530A (en) 2000-07-14 2002-08-28 Compositions containing alpha-2-adrenergic agonist components having enhanced solubility

Country Status (20)

Country Link
US (4) US6627210B2 (en)
EP (1) EP1365811A2 (en)
JP (3) JP4927298B2 (en)
KR (1) KR100757656B1 (en)
CN (2) CN101897704B (en)
AR (1) AR033539A1 (en)
AU (2) AU2001273269B2 (en)
BR (1) BR0109317A (en)
CA (1) CA2402405C (en)
HK (1) HK1060519A1 (en)
HU (1) HU0303197A3 (en)
IL (2) IL151530D0 (en)
MX (1) MXPA02008930A (en)
NO (1) NO333367B1 (en)
NZ (1) NZ521185A (en)
PL (1) PL360707A1 (en)
RU (1) RU2311928C2 (en)
TW (1) TWI287998B (en)
WO (1) WO2002005853A2 (en)
ZA (1) ZA200207413B (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL361027A1 (en) * 2000-07-14 2004-09-20 Allergan,Inc. Compositions containing therapeutically active components having enhanced solubility
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
IL151530D0 (en) * 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU2011250793B2 (en) * 2000-07-14 2012-11-29 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US6753017B2 (en) * 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
PL216373B1 (en) * 2002-10-08 2014-03-31 Allergan, Inc. Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
JP2006504741A (en) * 2002-10-08 2006-02-09 アラーガン、インコーポレイテッドAllergan,Incorporated Using (2-imidazolin-2-ylamino) quinoxaline in the treatment of dementia and Parkinson's disease
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
ES2424644T3 (en) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compounds, formulations and methods to treat or prevent inflammatory skin disorders
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
JP2007501799A (en) 2003-08-07 2007-02-01 アラーガン、インコーポレイテッドAllergan,Incorporated Compositions and methods of preparation and use thereof for delivering a medicament into an eye
CA2543458A1 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
JP4789454B2 (en) * 2004-12-03 2011-10-12 株式会社キーエンス Fluorescence microscope
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
EP1934203B1 (en) * 2005-08-25 2010-08-18 Schering Corporation 3,4-dihydro-2H-benzo[1,4]oxazine and 3,4-dihydro-2H-benzo[1,4]thiazine COMPOUNDS AS ALPHA2C ADRENORECEPTOR AGONISTS
US7700592B2 (en) * 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
JP2009506047A (en) * 2005-08-25 2009-02-12 シェーリング コーポレイションSchering Corporation Imidazole derivatives as functionally selective α2C adrenergic receptor agonists
US8003624B2 (en) * 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
BRPI0618643A2 (en) 2005-11-09 2011-09-06 Combinatorx Inc Composition comprising a pair of pharmaceuticals, the composition comprising a corticosteroid and immunosuppressive immunophilin-dependent non-steroid use kits and
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
CA2713878C (en) * 2008-02-15 2017-01-31 Bone Therapeutics Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
PT2252290T (en) * 2008-02-15 2018-02-14 Bone Therapeutics Sa Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US20120156244A1 (en) * 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
DK2320911T3 (en) * 2008-08-01 2014-11-03 Eye Therapies Llc Vasokonstriktionspræparater and methods of use thereof
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
WO2010017120A1 (en) * 2008-08-04 2010-02-11 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
AR073628A1 (en) 2008-10-07 2010-11-17 Schering Corp Analogs biaryl espiroaminooxazolina and espiroaminodiazolina modulators alpha2C adrenergic receptors, pharmaceutical compositions comprising them and use thereof in allergic rhinitis, cardiac disorders and other diseases
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CA2780267A1 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions and methods for stimulating hair growth
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev Compositions comprising brimonidine for treating erythema
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
KR20140091543A (en) 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
JP6511401B2 (en) 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドAllergan,Incorporated Sustained drug delivery implant
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
AU2014342017A1 (en) 2013-10-31 2016-06-02 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
WO2015097600A2 (en) 2013-12-24 2015-07-02 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL286080A (en) * 1961-11-30
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (en) 1972-02-29 1973-08-27 Pfizer New derivatives of quinoline, quinoxaline and quinazoline first pharmaceutical composition containing them
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JPH085779B2 (en) * 1989-09-22 1996-01-24 杏林製薬株式会社 Fleroxacin ophthalmic solution
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
GB9017353D0 (en) 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
IT1252692B (en) 1991-11-27 1995-06-23 Zambon Spa Pharmaceutical composition for ophthalmic use containing a non-steroidal anti-inflammatory and a decongestant as active ingredients
JPH05271053A (en) * 1992-03-27 1993-10-19 Lion Corp Stable eye lotion
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU6124494A (en) 1993-01-28 1994-08-15 University Of Iowa Research Foundation, The Ophthalmic uses of signa agonists
CA2173974C (en) 1993-10-13 2006-05-02 James A. Burke Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5994110A (en) 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5856329A (en) 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
ZA9605837B (en) 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
EP0834308A1 (en) 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
JP2001522358A (en) 1997-04-18 2001-11-13 アボツト・ラボラトリーズ Process for the preparation of highly pure 6,7-dichloro-5-nitro-2,3-dihydro-2,3-dione
MY116782A (en) * 1997-12-22 2004-03-31 Otsuka Pharma Co Ltd Water-soluble eye drop
WO1999043299A2 (en) 1998-02-26 1999-09-02 Abbott Laboratories Oral formulation for hydrophilic drugs
ES2203103T3 (en) 1998-04-07 2004-04-01 Alcon Manufacturing Ltd. ophthalmic compositions containing xanthan gum gelling.
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
AT289804T (en) 1998-10-08 2005-03-15 Hampar L Karagoezian Synergistic antimicrobial. dermatological and ophtahalmologische preparations containing a chlorite and hydrogen peroxide
IN185228B (en) * 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar Process for manufacturing topical ophthalmic preparations without systemic effects
PL361027A1 (en) * 2000-07-14 2004-09-20 Allergan,Inc. Compositions containing therapeutically active components having enhanced solubility
IL151530D0 (en) * 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components

Also Published As

Publication number Publication date
RU2311928C2 (en) 2007-12-10
CN100569291C (en) 2009-12-16
IL151530A (en) 2009-05-04
CN101897704A (en) 2010-12-01
BR0109317A (en) 2003-06-17
US20020032201A1 (en) 2002-03-14
ZA200207413B (en) 2004-04-08
NO20024221L (en) 2002-10-28
AR033539A1 (en) 2003-12-26
MXPA02008930A (en) 2003-03-31
NO20024221D0 (en) 2002-09-04
JP2008231122A (en) 2008-10-02
CA2402405A1 (en) 2002-01-24
WO2002005853A3 (en) 2003-09-12
CN101897704B (en) 2014-10-29
JP2012067128A (en) 2012-04-05
NO333367B1 (en) 2013-05-13
CN1460026A (en) 2003-12-03
KR100757656B1 (en) 2007-09-10
TWI287998B (en) 2007-10-11
US20030087893A1 (en) 2003-05-08
JP4927298B2 (en) 2012-05-09
AU2001273269B2 (en) 2005-08-11
AU7326901A (en) 2002-01-30
HK1060519A1 (en) 2010-08-27
US6673337B2 (en) 2004-01-06
EP1365811A2 (en) 2003-12-03
US20030027811A1 (en) 2003-02-06
NZ521185A (en) 2005-02-25
JP2004504279A (en) 2004-02-12
US20040063689A1 (en) 2004-04-01
CA2402405C (en) 2008-02-12
HU0303197A3 (en) 2008-03-28
WO2002005853A2 (en) 2002-01-24
KR20030017500A (en) 2003-03-03
US6627210B2 (en) 2003-09-30
US6641834B2 (en) 2003-11-04
HU0303197A2 (en) 2003-12-29
PL360707A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
JP2004515230A5 (en)
AP1699A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
MXPA03005605A (en) Pyrazole compounds useful as protein kinase inhibitors.
HK1057890A1 (en) Pyrazole compounds useful as protein kinase inhibitors.
ZA200402277B (en) Toll-like receptor 3 signaling agonists and antagonists.
GB2411989A (en) Providing a secure execution mode in a pre-boot environment
HU0104987A3 (en) Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
AU1046602A (en) Rotative cutting device, e.g. drill
ZA200205777B (en) Address acquisition.
PL376396A1 (en) Indole derivatives as beta-2 agonists
TW565488B (en) Fixed abrasive articles
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
MXPA04007637A (en) Pyrimidine compounds.
HK1036970A1 (en) Compounds and compositions for delivering active agents.
PL365874A1 (en) Dispersions for formulating slightly or poorly soluble active ingredients
AU9653701A (en) Determining alternative textual identifiers, such as for registered domain names
ME01309B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
NZ532048A (en) Inhibitors of post-proline cleaving proteases
AU4737201A (en) 5-amide substituted diarylamines as mex inhibitors
ZA200306734B (en) Metalloproteinase inhibitors.
CA2428905A1 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
AU3821601A (en) Stable, aqueous compositions for treating surfaces, especially fabrics
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
ZA200306282B (en) New composition.
ZA200007306B (en) Pyrazinone protease inhibitors.